We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+38.22%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.31B
AUM Growth
-$201M
Cap. Flow
-$428M
Cap. Flow %
-32.76%
Top 10 Hldgs %
91.01%
Holding
21
New
–
Increased
4
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$29.6M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$20.1M
3
CCCC icon
C4 Therapeutics
CCCC
+$14.4M
4
XLO icon
Xilio Therapeutics
XLO
+$2.11M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$289M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$124M
3
UPB
Upstream Bio Inc
UPB
+$27.6M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$22.2M
5
TNGX icon
Tango Therapeutics
TNGX
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTFL
1
Heartflow Inc
HTFL
$2.59B
$363M 27.79%
12,448,158
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.34B
$256M 19.63%
7,306,566
-3,412,544
-32% -$124M
OLMA icon
3
Olema Pharmaceuticals
OLMA
$1.06B
$213M 16.29%
8,508,641
+1,664,687
+24% +$29.6M
SVRA icon
4
Savara
SVRA
$1.19B
$106M 8.13%
17,600,621
– –
PHVS icon
5
Pharvaris
PHVS
$2.4B
$77.8M 5.96%
2,802,081
-379,194
-12% -$9.13M
SLDB icon
6
Solid Biosciences
SLDB
$907M
$44.6M 3.42%
7,911,669
– –
UPB
7
Upstream Bio Inc
UPB
$404M
$36.1M 2.76%
1,329,544
-1,109,994
-46% -$27.6M
XFOR icon
8
X4 Pharmaceuticals
XFOR
$447M
$31.9M 2.44%
7,967,454
+5,530,866
+227% +$20.1M
DNTH icon
9
Dianthus Therapeutics
DNTH
$6.13B
$30.6M 2.35%
743,592
-572,300
-43% -$22.2M
KYTX icon
10
Kyverna Therapeutics
KYTX
$491M
$29.2M 2.24%
3,110,000
-258,370
-8% -$1.92M
ANNX icon
11
Annexon
ANNX
$895M
$26.4M 2.02%
5,249,069
– –
RPID icon
12
Rapid Micro Biosystems
RPID
$86.7M
$24.5M 1.87%
8,434,560
– –
CABA icon
13
Cabaletta Bio
CABA
$455M
$21.2M 1.62%
9,677,125
– –
CCCC icon
14
C4 Therapeutics
CCCC
$408M
$13.7M 1.05%
7,171,910
+6,060,000
+545% +$14.4M
MRSN
15
DELISTED
Mersana Therapeutics
MRSN
$10M 0.77%
346,545
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$409M
$8.87M 0.68%
2,485,638
– –
TNGX icon
17
Tango Therapeutics
TNGX
$4.49B
$5.79M 0.44%
653,493
-2,058,515
-76% -$17.7M
XLO icon
18
Xilio Therapeutics
XLO
$59.2M
$4.72M 0.36%
526,620
+200,419
+61% +$2.11M
NAMSW icon
19
NewAmsterdam Pharma Warrant
NAMSW
$82.8M
$2.3M 0.18%
99,999
-1
-0% -$25
CDTX
20
DELISTED
Cidara Therapeutics
CDTX
– –
-3,020,990
Closed -$289M
IPSC icon
21
Century Therapeutics
IPSC
$361M
– –
-3,538,609
Closed -$1.76M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2025 Portfolio in Review

As of Q4 2025, Bain Capital Life Sciences Investors held 21 positions worth $1.31B, down 13% from $1.51B the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $428M in Q4 2025, closing 2 positions and reducing 7 holdings. Its most notable exit was Cidara Therapeutics, an estimated $289M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors added an estimated $29.6M to Olema Pharmaceuticals.

  • Bain Capital Life Sciences Investors added most to Olema Pharmaceuticals in Q4 2025, an estimated $29.6M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2025 reduction was NewAmsterdam Pharma, cutting an estimated $124M.
  • Bain Capital Life Sciences Investors fully exited Cidara Therapeutics in Q4 2025, selling an estimated $289M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 91% of its $1.31B portfolio in Q4 2025.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 2 in Q4 2025.
  • Bain Capital Life Sciences Investors's portfolio value fell 13% quarter-over-quarter to $1.31B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2025, filed 17 Feb 2026.